💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Hydromorphone

CHEMBL398707 Phase 4 معتمد Small molecule
Half-Life
2-3 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
285.3 g/mol
LogP
1.8
Phase
4

A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

الوزن الجزيئي

285,3380 g/mol

LogP

1,80

TPSA

49,80 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Migraine Obesity Hypertension Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

تصنيفات الأدوية

N — N - Nervous System

آلية العمل

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

الآلية

Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5

                

                

                
                

                    
InChI

                    
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H19NO3

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
الروابط القابلة للدوران

                        
0

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A potent opioid analgesic used to treat moderate to severe pain, including cancer pain and postoperative pain, by binding to opioid receptors in the central nervous system to reduce pain perception. It is several times more potent than morphine and is available in oral, intravenous, and subcutaneous formulations. Careful dose titration and monitoring for respiratory depression are essential during use.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Semisynthetic mu-opioid receptor agonist approximately 5 times more potent than morphine.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Hydromorphone: Half-life: 2-3 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Hydromorphone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL398707.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5284570.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.